Artemisinin‐based combination therapy for treating uncomplicated malaria
Información
- DOI:
- https://doi.org/10.1002/14651858.CD007483Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 08 octubre 2008see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Protocol
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Enfermedades infecciosas
- Copyright:
-
- Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
All authors were involved in the conception and design of this protocol. David Sinclair, Piero Olliaro, and Paul Garner drafted the protocol with statistical advice from Sarah Donegan. David Sinclair, Piero Olliaro, and Paul Garner revised the protocol following comments from the referees.
Sources of support
Internal sources
-
No sources of support supplied
External sources
-
Department for International Development (DFID), UK.
Declarations of interest
None known.
Acknowledgements
This document is an output from a project funded by the UK Department for International Development (DFID) for the benefit of developing countries.
Version history
| Published | Title | Stage | Authors | Version |
| 2009 Jul 08 | Artemisinin‐based combination therapy for treating uncomplicated malaria | Review | David Sinclair, Babalwa Zani, Sarah Donegan, Piero Olliaro, Paul Garner | |
| 2008 Oct 08 | Artemisinin‐based combination therapy for treating uncomplicated malaria | Protocol | David Sinclair, Babalwa Zani, Hasifa Bukirwa, Sarah Donegan, Piero Olliaro, Paul Garner | |
Keywords
MeSH
Medical Subject Headings (MeSH) Keywords
- Antimalarials [*therapeutic use];
- Artemisinins [*therapeutic use];
- Artesunate;
- Drug Combinations;
- Drug Therapy, Combination;
- Ethanolamines [therapeutic use];
- Fluorenes [therapeutic use];
- Lumefantrine;
- Malaria [drug therapy];
- Malaria, Falciparum [*drug therapy];
- Malaria, Vivax [*drug therapy];
- Mefloquine [therapeutic use];
- Parasitemia [drug therapy, parasitology];
- Pyrimethamine [therapeutic use];
- Quinolines [therapeutic use];
- Randomized Controlled Trials as Topic;
- Sulfadoxine [therapeutic use];
Medical Subject Headings Check Words
Humans;
| Question | Analysis | Comparisons |
| 1. How does artesunate plus amodiaquine perform?
| 1.1 | vs amodiaquine plus sulfadoxine‐pyrimethamine |
| 1.2 | vs artesunate plus sulfadoxine‐pyrimethamine | |
| 1.3 | vs artemether‐lumefantrine (6 doses) | |
| 1.4 | vs dihydroartemisinin‐piperaquine | |
| 1.5 | vs artesunate plus mefloquine | |
| 2. How does artemether‐lumefantrine (6 doses) perform?
| 2.1 | vs amodiaquine plus sulfadoxine‐pyrimethamine |
| 2.2 | vs artesunate plus sulfadoxine‐pyrimethamine | |
| 2.3 | vs artesunate plus amodiaquine | |
| 2.4 | vs dihydroartemisinin‐piperaquine | |
| 2.5 | vs artesunate plus mefloquine | |
| 3. How does dihydroartemisinin‐piperaquine perform?
| 3.1 | vs amodiaquine plus sulfadoxine‐pyrimethamine |
| 3.2 | vs artesunate plus sulfadoxine‐pyrimethamine | |
| 3.3 | vs artesunate plus amodiaquine | |
| 3.4 | vs artemether‐lumefantrine (6 doses) | |
| 3.5 | vs artesunate plus mefloquine | |
| 4. How does artesunate plus mefloquine perform?
| 4.1 | vs amodiaquine plus sulfadoxine‐pyrimethamine |
| 4.2 | vs artesunate plus sulfadoxine‐pyrimethamine | |
| 4.3 | vs artesunate plus amodiaquine | |
| 4.4 | vs artemether‐lumefantrine (6 doses) | |
| 4.5 | vs dihydroartemisinin‐piperaquine | |
| aTo contribute to informed decision‐making, the review is limited to artemisinin combination therapies (ACTs) for which co‐formulated products are currently available or shortly to be made available (trials using co‐packaged or loose preparations of these same ACTs are included). | ||
| Search set | CIDG SRa | CENTRAL | MEDLINEb | EMBASEb | LILACSb |
| 1 | malaria | malaria | malaria | malaria | malaria |
| 2 | arte* | arte* | arte* | arte* | arte* |
| 3 | dihydroarte* | dihydroarte* | dihydroarte* | dihydroarte* | dihydroarte* |
| 4 | amodiaq* | amodiaq* | amodiaq* | amodiaq$ | amodiaq$ |
| 5 | lumefantrine | lumefantrine | lumefantrine | lumefantrine | lumefantrine |
| 6 | Coartem* | Coartem* | Coartem* | Coartem$ | Coartem$ |
| 7 | mefloquine | mefloquine | mefloquine | mefloquine | mefloquine |
| 8 | 2 or 3 | 2 or 3 | 2 or 3 | 2 or 3 | 2 or 3 |
| 9 | 4 or 5 or 6 or 7 | 4 or 5 or 6 or 7 | 4 or 5 or 6 or 7 | 4 or 5 or 6 or 7 | 4 or 5 or 6 or 7 |
| 10 | 1 and 8 and 9 | 1 and 8 and 9 | 1 and 8 and 9 | 1 and 8 and 9 | 1 and 8 and 9 |
| 11 | — | — | Limit 10 to humans | Limit 10 to human | — |
| aCochrane Infectious Diseases Group Specialized Register. | |||||
| Analysis | Participants | PCRb‐adjusted | PCR‐unadjusted | ||
| Numerator | Denominator | Numerator | Denominator | ||
| Primary analysis | Exclusions after enrolment | Excludedc | Excluded | Excluded | Excluded |
| Missing or indeterminate PCR | Excluded | Excluded | Included as failures | Included | |
| New infections | Excluded | Excluded | Included as failures | Included | |
| Sensitivity analysis 1d | As 'Primary analysis' except: missing or indeterminate PCR | Included as failures | Included | — | — |
| Sensitivity analysis 2e | As 'Sensitivity analysis 1' except: new infections | Included as successes | Included | — | — |
| Sensitivity analysis 3f | As 'Sensitivity analysis 2' except: exclusions after enrolment | Included as failures | Included | Included as failures | Included |
| Sensitivity analysis 4g | As 'Sensitivity analysis 2' except: exclusions after enrolment | Included as successes | Included | Included as successes | Included |
| aNote: participants who were found to not satisfy the inclusion criteria after randomization are removed from all calculations. | |||||
